Moderna Shares Surge After Phase 3 Melanoma Vaccine Trial Meets Key Goals With Merck
Personalized mRNA therapy plus Keytruda improved recurrence-free and distant metastasis-free survival in resected high-risk melanoma patients, marking a first for the technology
